Evidence map›Paper›PMID 40182279›Full record

ArticleFrontiers in microbiology2025

Baicalein combined with azoles against fungi

Mengmin Liang, Qingwen Hu, Junhao Yu, Heng Zhang, Sijie Liu, Jiangrong Huang, Yi Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengmin LiangSchool of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, China.
Qingwen HuDepartment of Clinical Medicine, Yangtze University, Jingzhou, China.
Junhao YuDepartment of Clinical Medicine, Yangtze University, Jingzhou, China.
Heng ZhangDepartment of Dermatology, Jingzhou Hospital Affiliated to Yangtze University, Hubei Provincial Clinical Research Center for Diagnosis and Therapeutics of Pathogenic Fungal Infection, Jingzhou, China.
Sijie LiuSchool of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, China.
Jiangrong HuangEndocrinology Department, The Third Clinical College of Yangtze University, Traditional Chinese Medicine of Jingzhou Hospital, Jingzhou, China.
Yi SunDepartment of Dermatology, Jingzhou Hospital Affiliated to Yangtze University, Hubei Provincial Clinical Research Center for Diagnosis and Therapeutics of Pathogenic Fungal Infection, Jingzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Invasive fungal infections (IFIs) constitute a significant health challenge, particularly among immunocompromised individuals, characterized by a high prevalence and associated mortality rates. The synergistic administration of Baicalein (BE) with azole antifungal agents could potentially herald a novel therapeutic paradigm. Materials and methods: 54 Results: BE shows synergistic effects with POS and ITC, with 89.61% and 25.97% of fungal strains. The BE/POS regimen exerted synergistic effects in 87.04% of Conclusion:

Indexed as

Aspergillusbaicaleindematiaceous fungiitraconazoleposaconazolesynergy

Identifiers

PMID40182279
PMCPMC11966473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.